Our Take
The concern is real but framed as a policy failure, not a capability loss—China is still years behind in pharma output, and US venture capital remains unmatched.
Why it matters
Biotech leaders see NIH cuts as a strategic self-infliction at a moment when China is deliberately building a pharma industry to compete globally. Immigration restrictions compound the damage by discouraging foreign scientists from staying in the US.
Do this week
Biotech hiring managers: audit visa and remote-work policies now to retain international talent, since federal funding alone will not drive hiring for the next 18 months.
Federal cuts collide with China's decade-long biotech bet
Panelists at the BIO International Convention in San Diego (June 22–25, 2026) flagged a compound threat to US biotech leadership. The Trump administration eliminated federal funding to the National Institutes of Health, the primary funder of biomedical research. Simultaneously, China is executing a state-directed strategy to build indigenous drug companies with global reach, supported by approximately $1 trillion in annual R&D spending (per OECD figures cited by BIO chairman Fritz Bittenbender).
Bittenbender warned of "a generational loss of scientists," as NIH cuts disincentivize overseas researchers from relocating to the US. The comparison is stark: China's five-year plan explicitly targets global bioscience dominance, while the US is contracting public research investment at the moment of highest competitive pressure.
A GlobalData survey of biopharma professionals found that over 60% now view Chinese biotechs as either a competitive threat or as both partner and competitor, reflecting the breadth of Chinese innovation across drug modalities and therapy areas.
Capital flight and immigration policy create a two-front weakness
Andrew Lam, managing director at healthcare investor Ally Bridge Group, articulated a second vulnerability. He argued that US-imposed restrictions on foreign investment will not slow China's growth because "capital is fungible and moves around." If US policy tightens access to American pharma assets, money will seek innovation elsewhere, including China itself.
Oregon Governor Tina Kotek added a third layer: even state-level efforts to retain biotech talent (via cost-of-living improvements and post-pandemic remote-work flexibility) are undermined by federal immigration restrictions that limit the number of foreign biopharma workers able to contribute to the US industry.
The implication is clear. A combination of reduced federal funding, defensive capital controls, and restrictive immigration policy is eroding the US advantage in the single arena where it has maintained clear leadership: biotech innovation and deployment. China, by contrast, is using coordinated government spending and domestic incentives to close the gap within a decade.
The US still has one real moat: capital-market depth
Lam offered one counterweight: the US venture capital and public equity markets remain far deeper and more liquid than anything China can replicate in the medium term. This advantage buys time—but only if the US does not voluntarily surrender it through further policy restrictions.
The practical signal: biotech firms and investors should treat federal research funding as an unreliable source for the next 2–3 years and lean harder on private capital. Hiring and retention strategies should assume that visa and remote-work policies will remain restrictive, making it critical to compete on salary, equity, and quality-of-life factors that can offset the federal-funding headwind.